AXTI FY2025 GAAP gross margin falls to 12.7% of revenue (USD 88.33 million)

Reuters
02/20
AXTI FY2025 GAAP gross margin falls to 12.7% of revenue (USD 88.33 million)

AXT reported Q4 FY2025 revenue of USD 23.04 million, with GAAP gross margin of 20.9% and non-GAAP gross margin of 21.5%. The quarter’s GAAP net loss attributable to shareholders was USD 3.55 million (USD 0.08 per share), while non-GAAP net loss was USD 2.27 million (USD 0.05 per share). For FY2025, AXT posted revenue of USD 88.33 million, GAAP gross margin of 12.7% and non-GAAP gross margin of 13.1%. GAAP net loss attributable to shareholders was USD 21.26 million (USD 0.49 per share), compared with non-GAAP net loss of USD 17.97 million (USD 0.41 per share). Cash and cash equivalents were USD 120.27 million at Dec. 31, 2025. Management said it received fewer export permits than expected in Q4, but has received some permits in 2026 and expects sequential revenue growth in Q1, driven primarily by indium phosphide demand tied to AI infrastructure build-outs. The company also said it is broadening its customer base to include Tier-1 companies and remains on track to double indium phosphide manufacturing capacity in 2026. Separately, AXT said its China subsidiary Tongmei’s planned STAR Market IPO remains subject to review and approval by the CSRC and other authorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AXT Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602191605BIZWIRE_USPR_____20260219_BW561660) on February 19, 2026, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10